Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia.

BACKGROUND Epidemiologic studies have demonstrated strong and consistent associations between the detection of human papillomavirus (HPV) type 16 DNA and the risk of cervical intraepithelial neoplasia (CIN) and cervical cancer. However, HPV16 is also the most common type of HPV in the normal population, and only a minority of women with HPV16 infection develop cervical cancer. Studies of genomic heterogeneity in HPV16 have demonstrated the presence of multiple variant forms in all human populations examined to date. It is conceivable that the natural variants of HPV16 in a given population may not have the same biologic behavior. PURPOSE This study was designed to determine the association between natural variants of HPV16 and the risk of biopsy-confirmed CIN 2 or 3, the most important precancerous lesions of the uterine cervix. METHODS Prospective studies were conducted among 1) women attending a university and 2) women presenting to a sexually transmitted disease clinic. Subjects were eligible for inclusion in this investigation if the initial cytologic findings did not reveal CIN 2-3 and HPV16 DNA was detected by means of a polymerase chain reaction (PCR)-based method in one or more cervical or vulvovaginal samples. Eligible subjects were followed every 4 months with cervical Pap smears and colposcopic examinations. Women were referred for biopsy if cytology or colposcopy suggested CIN 2-3. Two groups of HPV16 variants, prototype-like and nonprototype-like, were determined by means of single-strand conformation polymorphism (SSCP) analysis of PCR products from the noncoding region of the viral genome. Representative SSCP patterns from HPV16 variants were further characterized by direct DNA sequencing of the PCR products. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated by Cox regression analysis. RESULTS Prototype-like variants accounted for 79% of the HPV16 detected in university students and 86% of the virus detected in patients presenting to the sexually transmitted disease clinic. CIN 2-3 was confirmed by biopsy in nine of 57 HPV16-positive women attending the university and in 10 of 66 HPV16-positive women presenting to the sexually transmitted disease clinic. Among university students, those with HPV16 nonprototype-like variants were 6.5 (95% CI = 1.6-27.2) times more likely to develop CIN 2-3 than those with prototype-like variants. A similar association was observed among women presenting to the sexually transmitted disease clinic (RR = 4.5; 95% CI = 0.9-23.8). CONCLUSIONS This study suggests that the risk of developing CIN 2-3 is not the same with all variants of HPV16 and that nonprototype-like variants confer a greater risk compared with prototype-like variants. The important genomic differences underlying this increased risk of CIN 2-3 remain to be determined.

[1]  C. Wheeler,et al.  Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization , 1997, Journal of clinical microbiology.

[2]  R. Shoemaker,et al.  Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance. , 1996, British Journal of Cancer.

[3]  R. Shoemaker,et al.  Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. , 1996, Journal of the National Cancer Institute.

[4]  G. Dekan,et al.  MRP and MDR1 gene expression in primary breast carcinomas. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Flens,et al.  Tissue distribution of the multidrug resistance protein. , 1996, The American journal of pathology.

[6]  T. Grogan,et al.  Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. , 1996, Blood.

[7]  G. Giaccone,et al.  Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. , 1996, The American journal of pathology.

[8]  Q. Zhu,et al.  Evidence that SP1 modulates transcriptional activity of the multidrug resistance-associated protein gene. , 1996, DNA and cell biology.

[9]  R. Shoemaker,et al.  Overlapping phenotypes of multidrug resistance among panels of human cancer‐cell lines , 1996, International journal of cancer.

[10]  D. Schadendorf,et al.  Membrane transport proteins associated with drug resistance expressed in human melanoma. , 1995, The American journal of pathology.

[11]  A. Halpern,et al.  Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments , 1995, Journal of virology.

[12]  R. Burk,et al.  Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.

[13]  K. Holmes,et al.  Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. , 1995, The Journal of infectious diseases.

[14]  G. Giaccone,et al.  Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. , 1995, Journal of the National Cancer Institute.

[15]  W. Walther,et al.  Gene transfer of human TNFα into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity , 1995, International journal of cancer.

[16]  H. Clevers,et al.  The drug resistance-related protein LRP is the human major vault protein , 1995, Nature Medicine.

[17]  P. Stern,et al.  The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer , 1995, Nature Medicine.

[18]  D. Hipfner,et al.  Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. , 1995, British Journal of Cancer.

[19]  B. Nielsen,et al.  Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. , 1995, Cancer research.

[20]  K. Khalili,et al.  Identification and characterization of a novel GGA/C-binding protein, GBP-i, that is rapidly inducible by cytokines , 1994, Molecular and cellular biology.

[21]  D. Cohen,et al.  NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. , 1994, The Journal of biological chemistry.

[22]  N. Borsellino,et al.  Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects. , 1994, Anticancer research.

[23]  W. Walther,et al.  RNA analysis using miniprep RNA in reverse transcription PCR. , 1994, BioTechniques.

[24]  F. Baas,et al.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Meijer,et al.  Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. , 1994, Cancer research.

[26]  W. Dalton,et al.  Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. , 1994, Cancer research.

[27]  Q. Zhu,et al.  Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. , 1994, Cancer research.

[28]  F. Stubenrauch,et al.  The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. , 1994, The EMBO journal.

[29]  D. Hipfner,et al.  Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.

[30]  W. Bonnez Taxonomy of the human papillomaviruses. , 1993, Clinical Infectious Diseases.

[31]  N. Kiviat,et al.  The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations , 1993, Journal of virology.

[32]  N. Kedersha,et al.  Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. , 1993, Journal of cell science.

[33]  N. Kiviat,et al.  Sequence variation in the noncoding region of human papillomavirus type 16 detected by single-strand conformation polymorphism analysis. , 1993, The Journal of infectious diseases.

[34]  M. M. Pater,et al.  Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNA-protein interactions , 1993, Journal of virology.

[35]  F. Herrmann,et al.  The mitogenic response to tumor necrosis factor alpha requires c-Jun/AP-1 , 1993, Molecular and cellular biology.

[36]  K. Kohno,et al.  Involvement of protein kinase in environmental stress‐induced activation of human multidrug resistance 1 (MDR1) gene promoter , 1993, FEBS letters.

[37]  S Wacholder,et al.  Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. , 1993, Journal of the National Cancer Institute.

[38]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[39]  N. Kiviat,et al.  Comparison of dot filter hybridization, Southern transfer hybridization, and polymerase chain reaction amplification for diagnosis of anal human papillomavirus infection , 1993, Journal of clinical microbiology.

[40]  K. Cowan,et al.  A Y-box consensus sequence is required for basal expression of the human multidrug resistance (mdr1) gene. , 1993, The Journal of biological chemistry.

[41]  S. Parodi,et al.  Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. , 1993, European journal of cancer.

[42]  A. Bollon,et al.  Tumor necrosis factor activities and cancer therapy--a perspective. , 1993, Pharmacology & therapeutics.

[43]  R. Burk,et al.  Taxonomy of the human papillomaviruses , 1993 .

[44]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[45]  T. Tsuruo,et al.  Purification and characterization of NF-R1 that regulates the expression of the human multidrug resistance (MDR1) gene. , 1992, Nucleic acids research.

[46]  K. Holmes,et al.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection , 1992, The New England journal of medicine.

[47]  L V Rubinstein,et al.  Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. , 1992, Cancer research.

[48]  J. Whitsett,et al.  Effects of TNF-alpha and phorbol ester on human surfactant protein and MnSOD gene transcription in vitro. , 1992, The American journal of physiology.

[49]  E. Negri,et al.  Risk factors for cervical intraepithelial neoplasia , 1992, Cancer.

[50]  B. Drescher,et al.  Molecular variants of human papillomavirus type 16 from four continents suggest ancient pandemic spread of the virus and its coevolution with humankind , 1992, Journal of virology.

[51]  M. Schiffman,et al.  Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. , 1992, Journal of the National Cancer Institute.

[52]  Lacey Cj Assessment of exposure to sexually transmitted agents other than human papillomavirus. , 1992 .

[53]  L. Koutsky,et al.  Natural history and epidemiological features of genital HPV infection. , 1992, IARC scientific publications.

[54]  J. Stephens,et al.  Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. , 1991, The Journal of biological chemistry.

[55]  S. Vermund,et al.  Human papillomavirus infection and other risk factors for cervical neoplasia: A case‐control study , 1991, International journal of cancer.

[56]  B. Storer,et al.  Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. , 1991, Cancer research.

[57]  K. Holmes,et al.  Histopathology of endocervical infection caused by Chlamydia trachomatis, herpes simplex virus, Trichomonas vaginalis, and Neisseria gonorrhoeae. , 1990, Human pathology.

[58]  E. de Villiers Heterogeneity of the human papillomavirus group , 1989, Journal of virology.

[59]  E. Villiers Heterogeneity of the human papillomavirus group. , 1989 .

[60]  P. Meltzer,et al.  Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. , 1989, Blood.

[61]  G. Nabel,et al.  Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[62]  L. Villa,et al.  Epidemiologic correlates of cervical neoplasia and risk of human papillomavirus infection in asymptomatic women in Brazil. , 1989, Journal of the National Cancer Institute.

[63]  B. Gloss,et al.  Numerous nuclear proteins bind the long control region of human papillomavirus type 16: a subset of 6 of 23 DNase I-protected segments coincides with the location of the cell-type-specific enhancer , 1989, Journal of virology.

[64]  K. Holmes,et al.  Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. , 1989, The Journal of infectious diseases.

[65]  K. Holmes,et al.  Epidemiology of genital human papillomavirus infection. , 1988, Epidemiologic reviews.

[66]  I. Pastan,et al.  Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. , 1987, The Journal of biological chemistry.

[67]  M. Braun,et al.  Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines , 1987, Journal of virology.

[68]  P Berg,et al.  Electroporation for the efficient transfection of mammalian cells with DNA. , 1987, Nucleic acids research.

[69]  J. Venditti,et al.  Pleiotropic resistance and drug development. , 1986, Progress in clinical and biological research.

[70]  S. Suhai,et al.  Human papillomavirus type 16 DNA sequence. , 1985, Virology.

[71]  M. Brattain,et al.  Heterogeneity of malignant cells from a human colonic carcinoma. , 1981, Cancer research.

[72]  C. Aldrich Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. , 1979, Journal of the National Cancer Institute.

[73]  J. Papadimitriou,et al.  An ultrastructural, cytochemical, and autoradiographic study of the mucous membrane of the human cervical canal with reference to subcolumnar basal cells. , 1979, The American journal of pathology.

[74]  D.,et al.  Regression Models and Life-Tables , 2022 .